Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: A questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto prefecture

Drug Safety

Volumn 36, Issue 10, 2013, Pages 981-987

  Kajiwara, Ayami ^a   Saruwatari, Junji ^a   Sakata, Misaki ^a   Morita, Kazunori ^a   Kita, Ayana ^a   Oniki, Kentaro ^a   Yamamura, Masato ^b   Murase, Motoji ^b   Koda, Haruo ^b   Hirota, Seisuke ^b   Ishizuka, Tadao ^a   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Medical Association   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; LINAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; BLURRED VISION; BODY MOVEMENT; CLINICAL PRACTICE; CONSTIPATION; COUGHING; DIABETES MELLITUS; DIARRHEA; DISEASE PREDISPOSITION; DIZZINESS; DROWSINESS; DRUG INDUCED DISEASE; DRUG SAFETY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; GASTRITIS; GLUCONEOGENESIS; HAND PARESTHESIA; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HUNGER; HYPOGLYCEMIA; JAPAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE REGRESSION; MUSCLE CRAMP; MUSCLE RIGIDITY; MYALGIA; NAUSEA; PERIODONTITIS; POLYPHARMACY; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; RHINOPHARYNGITIS; RISK FACTOR; SELF EVALUATION; SEX DIFFERENCE; SIDE EFFECT; STOMATITIS; STRUCTURED QUESTIONNAIRE; SWEATING; SYMPTOM; VERTIGO;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ALCOHOL DRINKING; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; LIVER DISEASES; MALE; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; SOCIETIES, PHARMACEUTICAL;

EID: 84885449887     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0077-z     Document Type: Article

References (27)

1. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf. 2011;6(5):304-9.
2. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609-29.
3. Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224-35.
4. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86(1):44-57.
5. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23(6):1329-39.
6. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171-80.
7. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205.
8. Simeone JC, Quilliam BJ. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database. Ann Pharmacother. 2012;46(2):157-68.
9. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-9.
10. Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, et al. Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011. Drug Saf. 2011;34(12):1191-202.
11. Japan Pharmaceutical Association. Annual Report of JPA 2010-2011 [online]. http://www.nichiyaku.or.jp/e/data/annual-report2010e.pdf. Accessed 14 March 2013.
12. Barnett AH, Cradock S, Fisher M, et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract. 2010;64(8):1121-9.
13. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-28.
14. Sumida KD, Hill JM, Matveyenko AV. Sex differences in hepatic gluconeogenic capacity after chronic alcohol consumption. Clin Med Res. 2007;5(3):193-202.
15. Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med. 2012;124(4):130-7.
16. Arky RA. Hypoglycemia associated with liver disease and ethanol. Endocrinol Metab Clin N Am. 1989;18(1):75-90.
17. Taborsky GJ Jr, Mundinger TO. Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology. 2012;153(3):1055-62.
18. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13(Suppl 1):89-94.
19. Charbonneau A, Unson CG, Lavoie JM. High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. J Physiol (Lond). 2007;579(Pt 1):255-67.
20. Iwasaki T, Tomeno W, Yoneda M, et al. Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology. 2012;59(117):1522-5.
21. Szalat A, Raz I. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab. 2008;10(12):1135-56.
22. Horton TJ, Grunwald GK, Lavely J, et al. Glucose kinetics differ between women and men, during and after exercise. J Appl Physiol. 2006;100(6):1883-94.
23. Færch K, Borch-Johnsen K, Vaag A, et al. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia. 2010;53(5):858-65.
24. Ahren B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clinl Endocrinol Metab. 2009;94(4):1236-43.
25. Pietraszek A, Gregersen S, Hermansen K. Alcohol and type 2 diabetes. A review. Nutr Metab Cardiovasc Dis. 2010;20(5):366-75.
26. Paolisso G, Monami M, Marfella R, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther. 2012;29(3):218-33.
27. Isacson D, Johansson L, Bingefors K, et al. Nationwide survey of subjectively reported adverse drug reactions in Sweden. Ann Pharmacother. 2008;42(3):347-53.